HomeCompareMYLKF vs JNJ

MYLKF vs JNJ: Dividend Comparison 2026

MYLKF yields 13157.89% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MYLKF wins by $828146685268522240.00M in total portfolio value
10 years
MYLKF
MYLKF
● Live price
13157.89%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$828146685268522240.00M
Annual income
$815,947,977,170,678,000,000,000.00
Full MYLKF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — MYLKF vs JNJ

📍 MYLKF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMYLKFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MYLKF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MYLKF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MYLKF
Annual income on $10K today (after 15% tax)
$1,118,421.05/yr
After 10yr DRIP, annual income (after tax)
$693,555,780,595,076,300,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, MYLKF beats the other by $693,555,780,595,076,300,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MYLKF + JNJ for your $10,000?

MYLKF: 50%JNJ: 50%
100% JNJ50/50100% MYLKF
Portfolio after 10yr
$414073342634261120.00M
Annual income
$407,973,988,585,339,000,000,000.00/yr
Blended yield
98.53%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

MYLKF
No analyst data
Altman Z
-11.7
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MYLKF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMYLKFJNJ
Forward yield13157.89%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$828146685268522240.00M$30.3K
Annual income after 10y$815,947,977,170,678,000,000,000.00$4,689.40
Total dividends collected$827338236264856448.00M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MYLKF vs JNJ ($10,000, DRIP)

YearMYLKF PortfolioMYLKF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$1,326,489$1,315,789.47$10,592$272.30+$1.32MMYLKF
2$164,539,053$163,119,709.01$11,289$357.73+$164.53MMYLKF
3$19,085,896,390$18,909,839,603.17$12,123$472.89+$19085.88MMYLKF
4$2,070,392,527,742$2,049,970,618,604.87$13,141$629.86+$2070392.51MMYLKF
5$210,043,286,645,888$207,827,966,641,204.62$14,408$846.81+$210043286.63MMYLKF
6$19,929,741,115,638,064$19,704,994,798,926,964.00$16,021$1,151.60+$19929741115.62MMYLKF
7$1,768,696,930,241,318,100$1,747,372,107,247,585,300.00$18,122$1,588.22+$1768696930241.30MMYLKF
8$146,820,868,449,548,910,000$144,928,362,734,190,690,000.00$20,930$2,228.20+$146820868449548.91MMYLKF
9$11,400,661,773,686,179,000,000$11,243,563,444,445,163,000,000.00$24,792$3,191.91+$11400661773686178.00MMYLKF
10$828,146,685,268,522,200,000,000$815,947,977,170,678,000,000,000.00$30,274$4,689.40+$828146685268522240.00MMYLKF

MYLKF vs JNJ: Complete Analysis 2026

MYLKFStock

The Planting Hope Company, Inc. produces health-based foods and snacks in the United States and Canada. It develops, launches, and scales nutritious consumer packaged foods and beverages. The company provides sesamemilk under the Hope & Sesame name; veggie chips under the Mozaics name; and nutritious plant-based snack products under the Veggicopia name. It sells its products through wholesale distributors, direct-to-business, direct-to-consumer, and retail channels. The company was formerly known as Campio Capital Corp. and changed its name to The Planting Hope Company, Inc. in May 2021. The Planting Hope Company, Inc. was incorporated in 2020 and is headquartered in Chicago, Illinois.

Full MYLKF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this MYLKF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MYLKF vs SCHDMYLKF vs JEPIMYLKF vs OMYLKF vs KOMYLKF vs MAINMYLKF vs ABBVMYLKF vs MRKMYLKF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.